PhRMA, top Democrats urge Supreme Court to take up abortion pill case
It’s a rarity these days to see the top pharma industry lobbying group join Senate and House Democrat leaders and argue the same side of any issue, but that’s the case with petitioning the Supreme Court to take up a case on the abortion pill mifepristone. The case could have ripple effects for all drug approvals.
PhRMA makes clear in an amicus brief filed last Thursday that the Fifth Circuit’s decision in August to restrict the use of mifepristone and its generic versions under the conditions for use that existed in 2016, before the FDA loosened some of the regulations, could lead to negative consequences for the pharma industry.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.